Autoimmune diseases

TYSABRI

TYSABRI (natalizumab) is a humanized monoclonal antibody and is the first alpha-4 antagonist in its class. The drug was designed to selectively inhibit immune cells from leaving the bloodstream and to prevent these cells from migrating into chronically inflamed tissue – the brain in multiple sclerosis and the gastrointestinal tract in Crohn's disease – where they may cause or maintain inflammation.

Ongoing clinical trials of TYSABRI include:

STRATA (Natalizumab re-initiation of dosing) will evaluate the safety of natalizumab monotherapy following re-exposure to natalizumab (during the first 48 weeks) and assess the long-term efficacy of natalizumab (for an additional 216 weeks).
TOP (TYSABRI observational program) is a five-year observational study to evaluate the long term safety and treatment impact of TYSABRI in patients in the commercial setting.
TYGRIS (TYSABRI global observational program in safety) is a 5-year, worldwide study to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events in patients with multiple sclerosis treated with TYSABRI (natalizumab).
CD INFORM is an observational study to determine the incidence and pattern of serious and/or clinically significant infections, malignancies, and other serious adverse events in moderate to severely active Crohn's disease patients treated with TYSABRI in a commercial setting.

Important Safety Information for Crohn's Disease

Important Safety Information for Multiple Sclerosis

Additional Autoimmune Clinical Trials

ELND002 is a subcutaneous injectable therapeutic currently in Phase 1 for relapsing forms of multiple sclerosis.

Please visit clinicaltrials.gov for more information about Elan's clinical trials.